Literature DB >> 22271712

The efficacy and toxicity of SIOP preoperative chemotherapy in Malawian children with a Wilms tumour.

Trijn Israels1, George Chagaluka, Dalida Pidini, Huib Caron, Jan de Kraker, Steve Kamiza, Eric Borgstein, Liz Molyneux.   

Abstract

BACKGROUND: In Malawi, preoperative chemotherapy for Wilms tumour is a logical strategy, but detailed information on toxicity and efficacy in such a resource limited setting has been unavailable. PROCEDURE: Patients diagnosed with a unilateral Wilms tumour received preoperative chemotherapy-a two-drug 4-week regimen for localized disease and 6 weeks of a three-drug regimen for metastatic disease. Estimated maximum tumour diameter, decrease in tumour size, resectability, stage distribution and haematological toxicity during therapy were documented.
RESULTS: At diagnosis, 28% of 72 patients had an estimated maximum tumour diameter of more than 25 cm; 29% of patients had metastases. Eight children (11%) died during preoperative chemotherapy. More than half (59%) of the patients developed moderate neutropenia (neutrophils <1.0 × 10(9) /L; CTC grade 3) and 27% severe neutropenia (CTC grade 4 neutrophils <0.5 × 10.9/L). Grade 4 neutropenia occurred significantly more frequently in children receiving the three-drug regimen compared to the two-drug regimen; 50% (10/20) versus 15% (6/40) (P = 0.004). Fifty-seven percent of all patients had CTC grade 4 anaemia (Hb < 6.5 g/dL) during treatment. Most tumours (92%, 56/61) showed a response to chemotherapy but 14% (8/58) remained unresectable.
CONCLUSION: Preoperative chemotherapy for Wilms tumour causes considerable haematological toxicity and treatment-related mortality in malnourished Malawian children. A significant number of children have unresectable disease despite preoperative chemotherapy. To reduce treatment related mortality, consideration should be given to starting treatment with reduced doses in acutely malnourished patients.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22271712     DOI: 10.1002/pbc.24088

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  5 in total

1.  Investigating Wilms' Tumours Worldwide: A Report of the OxPLORE Collaboration-A Cross-Sectional Observational Study.

Authors:  K Ford; S Gunawardana; E Manirambona; G S Philipoh; B Mukama; A Kanyamuhunga; P Cartledge; M J Nyoni; D Mwaipaya; J Mpwaga; Z Bokhary; T Scanlan; T Heinsohn; H Hathaway; R Mansfield; S Wilson; K Lakhoo
Journal:  World J Surg       Date:  2020-01       Impact factor: 3.352

2.  Neoadjuvant transcatheter arterial chemoembolization and systemic chemotherapy for the treatment of undifferentiated embryonal sarcoma of the liver in children.

Authors:  Min He; Jia-Bin Cai; Can Lai; Jun-Qing Mao; Jie-Ni Xiong; Zhong-Hai Guan; Lin-Jie Li; Qiang Shu; Mei-Dan Ying; Jin-Hu Wang
Journal:  World J Clin Cases       Date:  2022-07-06       Impact factor: 1.534

3.  Efficacy of Preoperative Chemotherapy in Treatment of Children With Wilms' Tumor: A Meta-Analysis.

Authors:  Jia Junjun; Zhou Xuelian; Kadel Dhruba; Xie Haiyang; Zhou Lin; Zheng Shusen
Journal:  Iran J Pediatr       Date:  2015-04-18       Impact factor: 0.364

4.  The impact of ethnicity on wilms tumor: characteristics and outcome of a South african cohort.

Authors:  D K Stones; G P Hadley; R D Wainwright; D C Stefan
Journal:  Int J Pediatr       Date:  2015-03-26

5.  Treating Nephroblastoma in Rwanda: Using International Society of Pediatric Oncology Guidelines in a Novel Oncologic Care Model.

Authors:  Cyprien Shyirambere; Mary Jue Xu; Shekinah Nefreteri Elmore; Temidayo Fadelu; Leana May; Neo Tapela; Denis Gilbert Umuhizi; Frank Regis Uwizeye; Caitlin Driscoll; Clemence Muhayimana; Vedaste Hategekimana; Fidel Rubagumya; Ignace Nzayisenga; Lawrence N Shulman; Tharcisse Mpunga; Leslie E Lehmann
Journal:  J Glob Oncol       Date:  2016-01-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.